Gilead Presents New Data on Biktarvy® and TAF-Based Regimens for the Treatment of HIV-1 in Children, Older Adults and Women

Gilead Presents New Data on Biktarvy® and TAF-Based Regimens for the Treatment of HIV-1 in Children, Older Adults and Women

Share this…Facebook0TwitterLinkedinReddit0emailFOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ: GILD) today announced 48-week results from a Phase 2/3 study (Study GS-US-380-1474) evaluating the efficacy and safety of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, BIC/FTC/TAF), a once-daily single tablet regimen, in virologically suppressed adolescents and children at least …